6
Oct
2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
stand 18A11

Medis ehf.

About Medis ehf.

Medis is a leader in pharmaceutical development and out licensing, offering a broad portfolio of quality pharmaceutical products and comprehensive registration dossiers and intellectual property since 1985. Medis is a powerful partner with a proven track record in securing regulatory approval prior to patent expiries and has obtained marketing authorizations in over 100 countries to date. We out-license products from the pipeline of our parent company, Teva. Medis ehf is 100% owned by Teva Pharmaceutical Industries Ltd (NYSE, TASE: TEVA).

Certifications

Meet us at

  • CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
    stand 18A11
  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Contact info

Products from Medis ehf. (27)

  • Alprazolam (Reformulation)

    Product Alprazolam (Reformulation)

    A four-strength anxiolytic tablet portfolio undergoing reformulation.

    Dosage form: Tablet Strengths: 0.25 mg, 0.5 mg, 1 mg and 2 mg Therapeutic area: Nervous system Key indication: Anxiety Product class: Anxiolytic Dossier status: Available Estimated CPP timi...
  • Amlodipine / Indapamide / Perindopril Arginine (Commercial)

    Product Amlodipine / Indapamide / Perindopril Arginine (Commercial)

    A three-component fixed-dose combination opportunity for partners seeking to expand their cardiovascular portfolio.

    Dosage form: Film-coated tablet Strengths: 5 mg/1.25 mg/5 mg, 5 mg/2.5 mg/10 mg, 10 mg/1.25 mg/5 mg and 10 mg/2.5 mg/10 mg Therapeutic area: Cardiovas...
  • Apremilast (Commercial)

    Product Apremilast (Commercial)

    An oral product opportunity associated with immune-mediated conditions, including plaque psoriasis and psoriatic arthritis.

    Dosage form: Film-coated tablet Strengths: 10 mg, 20 mg and 30 mg Therapeutic area: Antineoplastic and immunomodulating agents Key ind...
  • Atenolol (Reformulation)

    Product Atenolol (Reformulation)

    A three-strength beta-blocker opportunity undergoing reformulation.

    Dosage form: Tablet Strengths: 25 mg, 50 mg and 100 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Beta-blocking agent Dossier status: Available The three-...
  • Azacitidine (Pipeline)

    Product Azacitidine (Pipeline)

    An oral pipeline opportunity associated with maintenance therapy for adults with acute myeloid leukaemia.

    Dosage form: Film-coated tablet Strengths: 200 mg and 300 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Maintenance therapy for adults with acute myeloid le...
  • Bisoprolol Fumarate (Reformulation)

    Product Bisoprolol Fumarate (Reformulation)

    A broad cardiovascular portfolio opportunity with six strengths.

    Dosage form: Film-coated tablet Strengths: 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Beta-blocking agent E...
  • Dabrafenib (Pipeline)

    Product Dabrafenib (Pipeline)

    A targeted-oncology pipeline opportunity associated with metastatic melanoma and non-small-cell lung cancer.

    Dosage form: Hard capsule Strengths: 50 mg and 75 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indications: Metastatic melanom...
  • Dapagliflozin (Pipeline)

    Product Dapagliflozin (Pipeline)

    A single-agent oral pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 5 mg and 10 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Product class: Blo...
  • Dapagliflozin / Metformin (Pipeline)

    Product Dapagliflozin / Metformin (Pipeline)

    A fixed-dose combination pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 5 mg/850 mg and 5 mg/1000 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Produ...
  • Eltrombopag (Commercial)

    Product Eltrombopag (Commercial)

    A focused oral hematology opportunity associated with the management of thrombocytopenia.

    Dosage form: Film-coated tablet Strengths: 25 mg, 50 mg and 75 mg Therapeutic area: Blood and blood-forming organs Key indication: Thrombocytopenia Product class: ...
  • Empagliflozin (Pipeline)

    Product Empagliflozin (Pipeline)

    A two-strength oral pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 10 mg and 25 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Product class: Bl...
  • Enzalutamide (Pipeline)

    Product Enzalutamide (Pipeline)

    An oral oncology pipeline opportunity associated with prostate cancer.

    Dosage form: Film-coated tablet Strengths: 40 mg and 80 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Prostate cancer Product class: Endocrine th...

Medis ehf. Resources (2)